

INPLASY202640051

doi: 10.37766/inplasy2026.4.0051

Received: 15 April 2026

Published: 15 April 2026

**Corresponding author:**

ran ding

dingran415@tmu.edu.cn

**Author Affiliation:**

Tianjin Medical University.

Ding, R; Wang, ZZ; Yue, HR; Chen, QL.

**ADMINISTRATIVE INFORMATION****Support** - Tianjin Medical University.**Review Stage at time of this submission** - Preliminary searches.**Conflicts of interest** - None declared.**INPLASY registration number:** INPLASY202640051**Amendments** - This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 15 April 2026 and was last updated on 15 April 2026.**INTRODUCTION**

**Review question / Objective** P (Population): Study subjects: Subjects must be model animals with cardiac injury, including rats or mice, with no restrictions on gender, body size, species, or sample size. I (Intervention): Intervention measures: Administration of glycyrrhizic acid and glycerolic acid. C (Comparison): Control group: Feeding with distilled water or normal saline. O (Outcome): Outcome evaluation: Assessment of cardiac injury severity through inflammatory markers, oxidative stress, and left atrial systolic function indices. S (Study design): Study design: The study design employs an animal-controlled trial to ensure scientific validity and reliability.

**Condition being studied** Cardiovascular diseases (CVDs) constitute a category of heart and blood vessel disorders, including coronary artery disease (CAD), cerebrovascular diseases, rheumatic heart disease, and other conditions. CVDs are major causes of mortality and disability.

**METHODS**

**Participant or population** Study subjects: Subjects must be model animals with cardiac injury, including rats or mice, with no restrictions on gender, body size, species, or sample size.

**Intervention** Mice using glycyrrhizic acid intervention.

**Comparator** Mice feed with distilled water or normal saline.

**Study designs to be included** The study design employed an animal control trial.

**Eligibility criteria** Exclusion criteria include: systematic reviews, case reports, clinical studies, and cell experiments; preclinical studies unrelated to glycyrrhizic acid; duplicate publications; studies lacking experimental data; and studies with significant risk of bias in experimental results.

---

**Information sources** PubMed, Embase, Web of Science, Cochrane Library.

**Main outcome(s)** Inflammatory markers, oxidative stress, and left atrial systolic function indices were used to assess the degree of cardiac injury.

**Quality assessment / Risk of bias analysis** To assess the quality of the included studies, two reviewers independently evaluated the risk of bias using the 10 SYRCLE bias risk tools developed by the Experimental Animal Experiment Evaluation Center.

**Strategy of data synthesis** Statistical analysis was performed using Review Manager (RevMan) version 5.4.1 and STATA 15.1. The overall effect size was estimated using standardized mean difference (SMD) and its corresponding 95% confidence interval (CI) for outcome measures.

**Subgroup analysis** None.

**Sensitivity analysis** One article was excluded sequentially, and the remaining literature (n-1 article) was meta-analyzed and merged, and the results of the original meta-analysis were evaluated by observing the changes in the combined results, and whether the results of the original meta-analysis had changed significantly due to the influence of some studies.

**Country(ies) involved** China.

**Keywords** Glycyrrhizic acid, cardioprotective, preclinical, mechanisms, meta-analysis.

#### **Contributions of each author**

Author 1 - ran ding.

Email: 2670076142@qq.com

Author 2 - zizhao wang.

Email: 2670076142@qq.com

Author 3 - haoran Yue.

Email: 2670076142@qq.com

Author 4 - qingliang chen.

Email: 2670076142@qq.com